| Date | Company | Compound | Disease | Type of agreement | Therapeutic area | Type of Information |
|---|---|---|---|---|---|---|
| 2017-03-30 | Ipsen (France) Merrimack Pharmaceuticals (USA - MA) | Onivyde® (nanoliposomal irinotecan injection), generic Doxil® | product acquisition | Cancer - Oncology | Product acquisition | |
| 2017-03-30 | BMS (USA - NY) Foundation Medicine (USA - MA) | predictive biomarkers such as Tumor Mutational Burden (TMB) and Microsatellite Instability (MSI) | collaboration | Cancer - Oncology | Collaboration agreement | |
| 2017-03-30 | Merck KGaA (Germany) Avilion (UK) | anti IL-17 A/F Nanobody® | development | Inflammatory diseases | Development agreement | |
| 2017-03-30 | Jazz Pharmaceuticals (Ireland) Nippon Shinyaku (Japan) | Defitelio® (defibrotide sodium), Vyxeos® (cytarabine and daunorubicin liposome injection) | acute myeloid leukemia, adult and pediatric patients with hepatic veno-occlusive disease (VOD), with renal or pulmonary dysfunction following hematopoietic stem-cell transplantation (HSCT) | development - commercialisation | Cancer - Oncology - Rare diseases | Licensing agreement |
| 2017-03-30 | CytomX Therapeutics (USA - CA) | nomination | Cancer - Oncology | Nomination | ||
| 2017-03-30 | Sarepta Therapeutics (USA - MA) | member of the strategic and scientific advisory boards | nomination | Rare diseases - Genetic diseases - Neuromuscular diseases | Nomination | |
| 2017-03-28 | Theradiag (France) Miraca Life Sciences (USA - TX) | LISA TRACKER® monitoring assays | licensing | Licensing agreement | ||
| 2017-03-28 | BMS (USA - NY) The Parker Institute for Cancer Immunotherapy (USA - CA) the Cancer Research Institute (CRI) (USA - NY) | clinical research | Cancer - Oncology | Clinical research agreement | ||
| 2017-03-28 | Selvita (Poland) Menarini (Italy) | SEL24 | licensing | Cancer - Oncology | Licensing agreement | |
| 2017-03-28 | RegenXBio (USA - MD) | chief scientific officer | nomination | Rare diseases - Genetic diseases | Nomination | |
| 2017-03-28 | Plasticell (UK) Agency for Science, Technology and Research (A*STAR) (Singapore) Nanyang Technological University (Singapore) | human stem cell lines | research - R&D - licensing | R&D agreement | ||
| 2017-03-28 | osteogenic cell therapy and 3D cell culture models |
research - R&D | Technology - Services | R&D agreement | ||
| 2017-03-28 | LIDDS (Sweden) Uppsala University (Sweden) | cancer drugs using NanoZolid technology | research | Cancer - Oncology | Research agreement | |
| 2017-03-28 | Akcea Therapeutics (USA - MA), a subsidiary of Ionis Pharmaceuticals (USA - CA) | nomination | Cardiovascular diseases - Metabolic diseases - Rare diseases | Nomination | ||
| 2017-03-27 | Xbrane Biopharma (Sweden) | Spherotide production facility in Italy | validation of a production plant | Technology -Services | Validation of a production plant | |
| 2017-03-27 | Alexion Pharmaceuticals (USA - CT) | chief executive officer | nomination | Rare diseases - Genetic diseases | Nomination | |
| 2017-03-27 | Coherus Biosciences (USA - CA) | nomination | Nomination | |||
| 2017-03-24 | PureTech Health (USA - MA) Novartis (Switzerland) | two clinical-stage programs targeting the mechanistic target of rapamycin complex 1 (mTORC1) pathway | diseases related to immunosenescence | licensing | Immunological diseases | Establishment of a new subsidiary in the EU |
| 2017-03-24 | C4 Therapeutics (USA - MA) Calico (USA - CA) | small molecule protein degraders as therapeutic agents to remove certain disease-causing proteins | diseases of aging, including cancer | development commercialisation | Cancer - Oncology | Development agreement |
| 2017-03-23 | ImmunoCellular Therapeutics (USA - CA) Memgen (USA - TX | ICT-107, ICT-140 and ISF35 | clinical research | Cancer - Oncology | Clinical research agreement |
